Benjamin D. Pace

Benjamin D. Pace

Auto-generated profile, based on publicly available information

Benjamin D. Pace

Department of Psychiatry, University of Iowa, Iowa City, IA, United States

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 September 2023 in Brain Stimulation
Verified
Journal Article
Open access
NTNicholas T. Trapp
Nicholas T. Trapp
BPBenjamin D. Pace
Benjamin D. Pace
BNBrandon Neisewander
Brandon Neisewander
PEPatrick Ten Eyck
Patrick Ten Eyck
ABAaron D. Boes
Aaron D. Boes
The Beam F3 and 5.5 cm methods are the two most common targeting strategies for localizing the left dorsolateral prefrontal cortex (DLPFC) treatment site in repetitive transcranial magnetic stimulation (rTMS) protocols. This prospective, randomized, double-blind comparative effectiveness trial assesses the clinical outcomes for these two methods in a naturalistic sample of patients with major depressive disorder (MDD) undergoing clinical rTMS treatment. 105 adult patients with MDD (mean age = 43.2; range = 18-73; 66% female) were randomized to receive rTMS to the Beam F3 (n = 58) or 5.5 cm (n = 47) target. Between group differences from pre-to post-treatment were evaluated with the Patient Health Questionnaire-9 (PHQ-9) [primary outcome measure], Generalized Anxiety Disorder-7 (GAD-7), and clinician-administered Montgomery-Åsberg Depression Scale (MADRS). Primary treatment endpoint was completion of daily treatment series. Per-protocol analyses showed no statistically significant differences on any measure between the 5.5 cm and F3 groups (all p ≥ 0.50), including percent improvement (PHQ-9: 39% vs. 39%; GAD-7: 34% vs. 27%; MADRS: 40% vs. 38%), response rate (PHQ-9: 37% vs. 43%; GAD-7: 27% vs. 30%; MADRS: 43% vs. 43%), and remission rate (PHQ-9: 22% vs. 21%; MADRS: 20% vs. 19%). Post hoc analysis of anxiety symptom change while controlling for depression severity suggested more favorable anxiolytic effects with 5.5 cm targeting (p = 0.03). Similar antidepressant effects were observed with DLFPC rTMS using either the Beam F3 or 5.5 cm targeting method, supporting clinical equipoise in MDD patients with head circumference ≤ 60 cm. Comparison to MRI-based targeting and differential effects on anxiety symptoms require further investigation. ClinicalTrials.gov identifier: NCT03378570.

31 December 2024 in Transcranial Magnetic Stimulation
Verified
Journal Article
Open access
NTNicholas T. Trapp
Nicholas T. Trapp
VEVictoria A. Muller Ewald
Victoria A. Muller Ewald
BPBenjamin D. Pace
Benjamin D. Pace
LWLinder Wendt
Linder Wendt
LGLaren Garrett
Laren Garrett
ABAaron D. Boes
Aaron D. Boes